All three trials evaluated the prognostic effect of zolbetuximab plus chemotherapy as a first-line treatment for HER2-negative, CLDN 18.2-positive, locally advanced, unresectable or metastatic G/GEJ adenocarcinoma. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.